| Variable | True Prevalence of CAS = 1% | True Prevalence of CAS = 5% |
|---|---|---|
| Patients screened, n | 100,000 | 100,000 |
| Patients with CAS in population, n | 1,000 | 5,000 |
| Positive screening test result, n | ||
| Total | 8,860 | 12,300 |
| True-positive result | 940 | 4,700 |
| False-positive result | 7,920 | 7,600 |
| Patients sent to surgery (false-positive/true-positive), n/n | ||
| No confirmatory test | 8,860 (7,920/940) | 12,300 (7,600/4,700) |
| Angiography confirmation | 940 (0/940) | 4,700 (0/4700) |
| MRA confirmation | 1,685 (792/893) | 5,225 (760/4,465) |
| Strokes caused by angiographic confirmation, n | 106 | 148 |
| Perioperative strokes or death caused by surgery in patients with false-positive results, n | ||
| No confirmatory test | 246 | 236 |
| Angiography confirmation | 0 | 0 |
| MRA confirmation | 25 | 24 |
| Nonfatal myocardial infarction among patients undergoing CEA (false-positive/true-positive), n/n | ||
| No confirmatory test | 54 (48/6) | 79 (49/30) |
| Angiography confirmation | 6 (0/6) | 30 (0/30) |
| MRA confirmation | 10 (5/5) | 34 (5/29) |
| Outcome events in true-positives (no or angiographic confirmation/MRA confirmation), n/n | ||
| Medical treatment | 111/105 | 555/527 |
| CEA | 60/57 | 301/286 |
| Difference: events prevented by CEA | 51/48 | 254/241 |
| Perioperative events in false-positives (no confirmation/angiographic confirmation/MRA confirmation), n/n/n | ||
| Medical treatment | 0/0/0 | 0/0/0 |
| CEA | 246/106/25 | 236/148/24 |
| Difference: events prevented by CEA | 246/106/25 | 236/148/24 |
| Strokes and perioperative deaths caused or prevented by CEA in false-positives and true-positives, n | ||
| No confirmatory test | 195 events caused | 18 events prevented |
| Angiography confirmation | 55 events caused | 106 events prevented |
| MRA confirmation | 23 events caused | 217 events prevented |
| NNS to prevent 1 stroke over 5 years | ||
| No confirmatory test | Events caused > prevented | 5,556 |
| Angiography confirmation | Events caused > prevented | 944 |
| MRA confirmation | 4,348 | 461 |
| NNS to prevent 1 disabling stroke over 5 years | ||
| No confirmatory test | Events caused > prevented | 11,112 |
| Angiography confirmation | Events caused > prevented | 1,888 |
| MRA confirmation | 8,696 | 922 |
a. Screening and confirmatory testing assumptions were as follows: 1) The screening test is carotid duplex ultrasonography, with sensitivity for CAS 60% to 99% of 0.94 and
specificity of 0.92; 2) the confirmatory test is none, cerebral angiography (sensitivity and specificity, 100%), or MRA (sensitivity, 0.95; specificity, 0.90); 3) the true prevalence
is 1% in the general primary care population .65 years of age and 5% in high-risk patients; 4) the stroke complication rate with angiography is 1.2%; 5) all patients with
positive test results go to surgery; 6) the perioperative stroke or death rate with CEA (whether the test result was true-positive or false-positive) is 3.1% (as in the
Asymptomatic Carotid Surgery Trial [ACST]); 7) the perioperative nonfatal myocardial infarction rate with CEA (whether the test result was true-positive or false-positive)
is 0.6% (as in ACST); 8) "events" are all strokes and perioperative deaths 5 years after CEA; 9) the probability of an event is 11.8% for medical and 6.4% for treatment with
CEA (as in ACST); 10) one half of strokes prevented are nondisabling; and 11) no benefit is received from medical or CEA treatment for patients with false-positive screening
test results.
CAS = carotid artery stenosis; CEA = carotid endarterectomy; MRA = magnetic resonance angiography; NNS = number needed to screen.